Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea

BACKGROUND: Rixubis (recombinant factor IX, nonacog gamma) is indicated for the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis in hemophilia B patients. This real-world, postmarketing surveillance study aimed to evaluate the safety and effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Eun Jin, Hwang, Tai ju, Choi, Yong Mook, Kim, Hugh Chul, Yoo, Myung Chul, Song, Haylee, Badejo, Kayode
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784123/
https://www.ncbi.nlm.nih.gov/pubmed/33303707
http://dx.doi.org/10.5045/br.2020.2020225

Ejemplares similares

Ejemplares similares